⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17800725 | 0.81 | MCL1 (0.32) | — | |
| SCHEMBL2044602 | 0.65 | — | — | |
| SCHEMBL1571817 | 0.60 | — | — | |
| SCHEMBL73411 | 0.60 | — | — | |
| SCHEMBL1948281 | 0.60 | — | — | |
| SCHEMBL1424511 | 0.60 | — | — | |
| SCHEMBL1529258 | 0.56 | — | — | |
| SCHEMBL1490037 | 0.55 | HPGD (0.47) | — | |
| SCHEMBL30442982 | 0.55 | ALOX15 (0.43) | — | |
| SCHEMBL22861454 | 0.54 | ALOX15 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230043835-A1 | Compounds for the Treatment of Kinase-Dependent Disorders | EXELIXIS, INC. | 2023-02-09 | — | — | US | claimed |
| EP-3980404-A1 | COMPOUNDS FOR THE TREATMENT OF KINASE-DEPENDENT DISORDERS | Exelixis, Inc. (US) | 2022-04-13 | — | — | EP | claimed |
| CN-114040912-A | Compounds for the treatment of kinase-dependent disorders | 埃克塞里艾克西斯公司 | 2022-02-11 | — | — | CN | claimed |
| WO-2020247418-A1 | COMPOUNDS FOR THE TREATMENT OF KINASE-DEPENDENT DISORDERS | EXELIXIS, INC. (US) | 2020-12-10 | — | — | WO | claimed |
| US-9994529-B2 | Amino quinazolines as kinase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-06-12 | — | — | US | claimed |
| US-20170152233-A1 | AMINO QUINAZOLINES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-06-01 | — | — | US | claimed |
| CN-105899489-A | Trifluoromethyl pyrazolyl guanidine F1FO-ATPase inhibitors and therapeutic uses thereof | 莱斯拉公司 | 2016-08-24 | — | — | CN | claimed |
| CN-102264722-B | Dihydropyridone amides as p2x7 modulators | HOFFMANN LA ROCHE | 2014-04-02 | — | — | CN | claimed |
| US-8163929-B2 | Dihydropyridone amides as P2X7 modulators | ROCHE PALO ALTO LLC (US) | 2012-04-24 | — | — | US | claimed |
| CN-102264722-A | Dihydropyridone amides as p2x7 modulators | — | 2011-11-30 | — | — | CN | claimed |
| EP-2382202-A1 | DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS | F. Hoffmann-La Roche AG (CH) | 2011-11-02 | — | — | EP | claimed |
| WO-2010072607-A1 | DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-07-01 | — | — | WO | claimed |
| US-20100160384-A1 | DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS | ROCHE PALO ALTO LLC | 2010-06-24 | — | — | US | claimed |
| US-20060122234-A1 | Substituted thienyl-hydroxamic acids as histone deacetylase inhibitors | ARGENTA DISCOVERY LIMITED | 2006-06-08 | — | — | US | claimed |
| CN-1684957-A | Substituted thienyl-hydroxamic acids as histone deacetylase inhibitors | ARGENTA DISCOVERY LTD (GB) | 2005-10-19 | — | — | CN | claimed |
| EP-1525199-A1 | SUBSTITUTED THIENYL-HYDROXAMIC ACIDS AS HISTONE DEACETYLASE INHIBITORS | Argenta Discovery Limited (GB) | 2005-04-27 | — | — | EP | claimed |
| WO-2004013130-A1 | SUBSTITUTED THIENYL-HYDROXAMIC ACIDS AS HISTONE DEACETYLASE INHIBITORS | ARGENTA DISCOVERY LIMITED (GB) | 2004-02-12 | — | — | WO | claimed |
| US-20230043835-A1 | Compounds for the Treatment of Kinase-Dependent Disorders | EXELIXIS, INC. | 2023-02-09 | — | — | US | disclosed |
| WO-2004013130-A1 | SUBSTITUTED THIENYL-HYDROXAMIC ACIDS AS HISTONE DEACETYLASE INHIBITORS | ARGENTA DISCOVERY LIMITED (GB) | 2004-02-12 | — | — | WO | disclosed |
| EP-0942909-B1 | BICYCLIC AMINE DERIVATIVES | SYNGENTA LTD (GB) | 2002-06-12 | — | — | EP | disclosed |